So this biotech fund just dumped like $75 million worth of Xenon Pharmaceuticals shares in Q4 - that's a pretty massive trim. They went from bigger holdings down to about 2.6% of their portfolio, which honestly feels strategic rather than panic. The thing is, Xenon's got Phase 3 data coming up in March for their epilepsy drug, and that's the whole story here. Either it works and the stock probably runs, or it doesn't and yeah, things get ugly fast. The stock's only up 6% over the past year anyway, which is rough for biotech. Xenon's trading around $42 with a pretty wide pipeline - 380 patients in the main trial, plus five other Phase 3 studies running. The fund basically sized down to spread risk instead of betting everything on one binary event. Smart move honestly, especially in biotech where one bad data readout can wreck you. Makes you think about whether the upside is worth the concentration risk at this point.